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Balázs Schäfer,a Erika Orbán,b† Zoltán Kele,c and Csaba Tömbölya*Cell membrane association of proteins can be achieved by the addition of lipid moieties to the polypeptide chain, and such
lipid-modiﬁed proteins have important biological functions. A class of cell surface proteins contains a complex
glycosylphosphatidylinositol (GPI) glycolipid at the C-terminus, and they are accumulated in cholesterol-rich membrane
microdomains, that is, lipid rafts. Semisynthetic lipoproteins prepared from recombinant proteins and designed lipids are
valuable probes and model systems of the membrane-associated proteins. Because GPI-anchored proteins can be reinserted
into the cell membrane with the retention of the biological function, they are appropriate candidates for preparing models
via reduction of the structural complexity. A synthetic headgroup was added to the 3β-hydroxyl group of cholesterol, an
essential lipid component of rafts, and the resulting cholesterol derivative was used as a simpliﬁed GPI mimetic. In order
to quantitate the membrane integrated GPI mimetic after the exogenous addition to live cells, a tritium labelled cholesterol
anchor was prepared. The radioactive label was introduced into the headgroup, and the radiolabelled GPI mimetic anchor
was obtained with a speciﬁc activity of 1.37 TBq/mmol. The headgroup labelled cholesterol derivative was applied to
demonstrate the sensitive detection of the cell membrane association of the anchor under in vivo conditions.
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A unique class of cell membrane-associated proteins contains a
C-terminal glycosylphosphatidylinositol (GPI) moiety, and these
lipoproteins associate with the outer leaﬂet of the membrane
bilayer via the lipid chains of the GPI molecule. GPI-anchored
proteins are functionally diverse including enzymes, cell
adhesion molecules, receptors, complement regulatory
proteins, immunoproteins and further proteins (e.g. prion
protein) with unknown functions.1 It was shown that their
biological functions were retained after exogenous addition to
membranes2–5; therefore, semisynthetic lipoproteins
containing diverse reporters in the headgroup of the lipid
moiety can be valuable probes for investigating GPI-anchored
proteins.6–13 The GPI moiety directs the attached protein
towards the extracellular space and locates the attached
protein in special membrane microdomains, that is, lipid rafts.
Because cholesterol maintains the dynamic lipid–lipoprotein
associates of GPI-anchored proteins, sphingolipids and
cholesterol,14,15 it is hypothesized that cholesteryl lipoproteins
may also be accumulated in lipid rafts.16 Based on the ﬁnding
that cholesteryl poly(ethylene glycol) ethers accumulate in
cholesterol-rich membranes and their cytotoxicity is low,17 we
have recently prepared a cholesterol derivative containing both
a maleimide and a ﬂuorescent reporter in the headgroup for
protein conjugation and imaging, respectively. It was shown
that after protein conjugation, the semisynthetic cholesteryl
lipoprotein could be puriﬁed via a β-cyclodextrin inclusion
complex that made the cholesterol moiety soluble in polar
solvents. Then, the lipid excess- and detergent-free lipoproteinJ. Label Compd. Radiopharm 2015, 58 7–13could be introduced into the cell membrane of live cells with
minimal disruption of the membrane, and the ﬂuorescence of
the headgroup could be unambiguously assigned to the
attached protein.18 In order to further study the membrane-
associated cholesteryl lipoproteins, it is important to quantitate
the lipoprotein incorporated into the cell membrane. It can be
achieved by determining the radioactivity of cell membrane
preparations or intact cells treated with a tritium labelled
analogue of the anchor molecule. Herein, we report our results
on the preparation and biological application of a tritium
labelled cholesterol derivative designed for that purpose.Copyright © 2015 John Wiley & Sons, Ltd.
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The purity of all reagents and solvents was analytical or the highest
commercially available grade. Protected propargylglycine (Pra) and
5-amioﬂuorescein were purchased from Bachem Feinchemicalen AG
(Bubendorf, Switzerland), and coupling reagents and substituted di
(ethylene glycols) were obtained from Calbiochem-Novabiochem AG
(Läufelﬁngen, Switzerland). Other chemicals were from Sigma Ltd. (St.
Louis, MO, USA). Tritium labelling was carried out in a self-designed
vacuum manifold,19,20and radioactivity was measured with a Packard
Tri-Carb 2100 TR liquid scintillation analyser using Hionic-Fluor
scintillation cocktail of PerkinElmer (Waltham, MA, USA). Analytical thin
layer chromatography (TLC) was performed on 5 × 10 cm glass plates
precoated with silica gel 60 F254 (Merck, Darmstadt, Germany), spots
were visualized with UV light, ninhydrin or phosphomolybdic acid, and
radioactivity was detected with a Berthold LB511 linear TLC analyser.
Flash chromatography was carried out on silica gel 60 (Sigma Ltd., St.
Louis, MO, USA) using the indicated solvents. Analytical and
semipreparative HPLC separations were performed with a Merck-Hitachi
LaChrom system under the indicated conditions. Radio-HPLC was
performed on a Jasco HPLC system equipped with a Packard Radiomatic
505 TR Flow Scintillation Analyser. NMR spectra were recorded on a
Bruker Spectra DRX 500MHz spectrometer in the indicated solvent, and
chemical shifts (δ) are reported in ppm after calibration to the solvent
signals. Molecular weights of the compounds were determined by MS
analysis on a Finnigan TSQ 7000 spectrometer equipped with an ESI
source or on a Bruker reﬂex III MALDI-TOF spectrometer. In the case of
MALDI-MS, 2,5-dihydroxybenzoic acid matrix was applied. Mass
spectrometric measurements of [2H]piperidine were performed on a
Micromass Q-TOF Premier mass spectrometer (Waters MSTechnologies,
Manchester, UK) equipped with a nanoelectrospray ion source. The
instrument was scanned in the mass range of 85–90. Peak intensities were
calculated for [M+H]+, [M(2H1) + H]
+, [M(2H2) + H]
+ and [M(2H3) + H]
+
molecule ions by the Masslynx software. The measured peak intensities
of mono-, di- and tri-deuterated ions were corrected by the calculated
intensities of overlapping [M(13C) + H]+, [M(2H1,
13C) + H]+ and [M
(2H2,
13C) + H]+ peaks, respectively. The effects of [M(13C2) + H]
+ and [M
(2H1,
13C2) + H]
+ and 15N containing ions were neglected. Live cells
treated with the ﬂuorescent anchor were visualized with an Olympus
IX81 confocal laser scanning microscope, and images were prepared by
the FluoView 500 software.[2H]piperidine (1)
An amount of 5mg of 4-bromopiperidine hydrobromide (20 μmol) was
dissolved in 400 μL of 10M NaOH, and it was extracted with 1mL of
EtOAc. The organic phase was washed with brine, dried over Na2SO4
and evaporated at atmospheric pressure. The resulting amine was
dissolved in 500 μL of EtOAc, and it was reduced under 0.4 bar deuterium
gas in the presence of 11mg of Pd/C (10% Pd) catalyst. After 3 h, the
catalyst was ﬁltered off, and the EtOAc solution was extracted with 1M
HCl. [2H]piperidine hydrochloride (1) was obtained after repeated
evaporations from the acidic aqueous solution (2mg, 82%). Rf 0.38 (n-
BuOH–AcOH–H2O 2:1:1); ESI-MS calcd for C5H10DN 86.10, found 87.09
[M + H]+.[3H]piperidine
Tritium labelling was performed with 2.1mg of 4-bromopiperidine base
(12.9 μmol) dissolved in 1mL of EtOAc in the presence of 5mg of Pd/C
(10% Pd) catalyst. The reaction mixture was degassed prior to tritium
reduction by a freeze–thaw cycle, and then it was stirred under 0.4 bar
of tritium gas for 3 h, followed by the ﬁltration of the catalyst. The EtOAc
solution was extracted with 1M HCl, and labile tritium was removed by
repeated evaporations from 1M HCl solution. Finally, 20.5 GBq of [3H]
piperidine hydrochloride was isolated as a white solid (s.a. 1.58 TBq/
mmol), which was immediately used for the next step.www.jlcr.org Copyright © 2015 Joh[3H]N-nitrosopiperidine
The solid [3H]piperidine hydrochloride (20.5 GBq) was dissolved in 100 μL
of 1M HCl, and the solution was cooled into ice. Then, 250mg of KNO2
was added, and the reaction mixture was stirred at 0 °C for 2 h followed
by extraction with Et2O. The ethereal solution was evaporated at
atmospheric pressure yielding 17.8 GBq (87%) of crude [3H]N-
nitrosopiperidine. It was dissolved in 100 μL THF and immediately used
in the next step without further puriﬁcation. Rf 0.28 (petroleum
etheracetone 9:1), 93% radiochemical purity by radio-TLC.
[3H]N-aminopiperidine (2)
The solution of 17.8 GBq of [3H]N-nitrosopiperidine in 100 μL of THF was
transferred to a reaction vessel equipped with a condenser. A suspension
of 4.5mg of LiAlH4 in 600 μL of THF was added, and the reaction mixture
was stirred under Ar at 60 °C for 3.5 h. After cooling, 100 μL of 10M NaOH
was added, and it was stirred for further 20min. The resulting slurry was
extracted with Et2O, and the ethereal solution was extracted with 3M
HCl. The HCl solution was evaporated, and labile tritium was removed
by repeated evaporations from water : ethanol (1:1), resulting in 8.4 GBq
(47%) of solid [3H]N-aminopiperidine hydrochloride (0.8 mg), which was
used for the preparation of 8 without further puriﬁcation. Rf 0.38 (n-
BuOHAcOHH2O 2:1:1), 73% radiochemical purity by radio-TLC, s.a.
1.33 TBq/mmol.
Cholesteryl (S)-1-(4-(2-(tert-butoxycarbonylamino)-2-
carboxyethyl)-1H-1,2,3-triazol-1-yl)-13-oxo-3,6,9-trioxa-12-
azahexadecan-16-oate (3)
Boc-Pra-OH (60mg, 281.4μmol) was dissolved in 1mL of dimethylformamide
(DMF), and it was added to the solution of cholesteryl 1-azido-13-oxo-3,6,9-
trioxa-12-azahexadecan-16-oate18 (230mg, 335.0μmol) in CH2Cl2 (4mL).
Then, a solution of L(+)-ascorbic acid sodium salt (33.4mg, 168.8μmol) and
CuSO4.5H2O (21.1mg, 84.4μmol) in water (4mL) was added. The reaction
mixture was stirred for 8 h at room temperature, and then it was evaporated
in vacuo. The crude product was puriﬁed by column chromatography
(CHCl3MeOHAcOH 90:9:1) to give 230.4mg (91%) of pure 3 as a white
solid. Rf 0.30 (CHCl3MeOHAcOH 90:9.5:0.5); k′=8.61 (tR = 12.5min; Vydac
214TP5410 C4 column (100 × 4.6mm, 5 μm), gradient elution with 1.8%/min
acetonitrile (ACN) (0.08% (v/v) triﬂuoroacetic acid (TFA) in H2O (0.1%(v/v)
TFA) starting from 50% ACN, ﬂow rate: 1mL/min, λ = 216 nm); 1H NMR
(500MHz, CDCl3) δ 7.63 (s, 1H), 6.63 (s, 1H), 5.61 (s, 1H), 5.34 (d, 1H,
J= 3.7 Hz), 4.58 (s, 2H), 4.53 (m, 1H), 4.47 (s, 1H), 3.86 (s, 2H), 3.60 (m, 10H),
3.42 (q, 2H, J=4.6 Hz), 3.28 (m, 2H), 2.62 (t, 2H, J=6.7Hz), 2.47 (t, 2H,
J= 6.7 Hz), 2.29 (d, 2H, J= 7.6 Hz), 1.98 (m, 1H), 1.93 (m, 1H), 1.83 (m, 3H),
[1.62–1.00 (m, 18H): 1.57 (3H), 1.52 (1H), 1.48 (2H), 1.40 (1H), 1.32 (1H), 1.30
(2H), 1.20 (1H), 1.14 (1H), 1.11 (4H), 1.09 (2H)], 1.42 (s, 9H), 1.00 (s, 3H),
[0.99–0.86 (m, 3H): 0.94 (2H), 0.88 (1H)], 0.90 (d, 3H, J=6.4 Hz), [0.86 (d, 3H,
J= 1.8 Hz), 0.84 (d, 3H, J=1.8Hz)], 0.66 (s, 3H); 13C NMR (125MHz, CDCl3) δ
172.7, 172.1, 155.7, 142.7, 139.7, 124.1, 122.7, 80.0, 74.5, 70.7, 70.5, 70.3,
70.1, 69.9, 69.5, 56.8, 56.2, 53.3, 50.5, 50.1, 42.4, 39.8, 39.6, 39.3, 38.2, 37.1,
36.7, 36.3, 35.9, 32.0 (2C), 31.0, 30.0, 28.5, 28.3, 28.12, 28.07, 27.8, 24.4, 23.9,
22.9, 22.7, 21.1, 19.4, 18.8, 12.0; MS(MALDI) calcd for C49H81N5O10 899.60,
found 900.44 [M+H]+.
Cholesteryl (S)-1-(4-(2-amino-2-carboxyethyl)-1H-1,2,3-
triazol-1-yl)-13-oxo-3,6,9-trioxa-12-azahexadecan-16-oate
(4)
Compound 3 (200mg, 222.3 μmol) was dissolved in 2mL of TFACH2Cl2
1:1, and it was stirred for 30min. The solution was evaporated in vacuo to
give 197.0mg (97%) of pure 4 triﬂuoroacetate as a pale yellow solid. Rf
0.12 (CHCl3–MeOH–AcOH 90:9.5:0.5); k′ = 4.15 (tR = 6.7min; Vydac
214TP5410 C4 column (100 × 4.6mm, 5 μm), gradient elution with
1.8%/min ACN (0.08% (v/v) TFA) in H2O (0.1%(v/v) TFA) starting from
50% ACN, ﬂow rate: 1mL/min, λ = 216 nm); MS(MALDI) calcd for
C44H73N5O8 799.55, found 800.48 [M + H]
+.n Wiley & Sons, Ltd. J. Label Compd. Radiopharm 2015, 58 7–13
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9Cholesteryl (S)-1-(4-(2-carboxy-2-(3-(maleimido)
propanamido)ethyl)-1H-1,2,3-triazol-1-yl)-13-oxo-3,6,9-
trioxa-12-azahexadecan-16-oate (5)
The amino acid derivative 4 (140mg, 153.2μmol) and N-ethyldiisopropylamine
(DIEA) (61 μL, 350.4 μmol) were dissolved in MeOH (4 mL), and 3-
maleimidopropionic acid N-hydroxysuccinimide ester (56.0mg, 210.4μmol)
was added. Themixture was stirred for 3 h at room temperature, and then it
was evaporated in vacuo. The crude product was puriﬁed by column
chromatography (CHCl3–MeOH–AcOH 85:14:1) to give 118mg (81%) of
pure 5 as a white solid. Rf 0.43 (CHCl3–MeOH–AcOH 80:19:1); k′= 6.53
(tR = 9.8min; Vydac 214TP5410 C4 column (100 × 4.6mm, 5 μm), gradient
elution with 1.8%/min ACN (0.08% (v/v) TFA) in H2O (0.1%(v/v) TFA) starting
from 50%ACN, ﬂow rate: 1mL/min, λ = 216 nm); 1H NMR (500MHz, CDCl3) δ
7.70 (s, 1H), 7.02 (brs, 1H), 6.68 (s, 2H), 6.63 (brs, 1H), 5.34 (d, 1H, J= 3.7Hz),
4.77 (brs, 1H), 4.57 (m, 2H), 4.49 (s, 1H), 3.82 (m, 4H), 3.61 (m, 10H), 3.42 (q,
2H, J= 4.6Hz), 3.24 (m, 2H), 2.62 (t, 2H, J= 6.7 Hz), 2.58 (t, 2H, J= 6.3 Hz),
2.47 (t, 2H, J= 6.7Hz), 2.30 (d, 2H, J= 7.6Hz), 2.01 (m, 1H), 1.94 (m, 1H),
1.83 (m, 3H), [1.62–1.03 (m, 18H): 1.57 (3H), 1.52 (1H), 1.48 (2H), 1.40 (1H),
1.32 (1H), 1.30 (2H), 1.20 (1H), 1.14 (1H), 1.11 (4H), 1.09 (2H)], 1.00 (s, 3H),
[0.99–0.86 (m, 3H): 0.94 (2H), 0.88 (1H)], 0.90 (d, 3H, J= 6.4Hz), [0.86 (d, 3H,
J= 1.8 Hz), 0.84 (d, 3H, J= 1.8 Hz)], 0.66 (s, 3H); 13C NMR (125MHz, CDCl3) δ
172.80, 172.7, 172.2, 170.7, 169.9, 142.7, 139.8, 134.3, 124.3, 122.8, 74.5,
70.6, 70.5, 70.3, 70.0, 69.9, 69.4, 56.8, 56.3, 53.5, 50.5, 50.1, 42.4, 39.8, 39.6,
39.4, 38.2, 37.1, 36.7, 36.3, 35.9, 34.6, 34.3, 32.0 (2C), 31.0, 30.0, 28.4, 28.1
(2C), 27.9, 24.4, 24.0, 23.0, 22.7, 21.2, 19.4, 18.8, 12.0; MS(MALDI) calcd for
C51H78N6O11 950.57, found 951.45 [M+H]
+.
Fluorescent cholesterol anchor 6
The maleimide derivative 5 (50mg, 52.6μmol) and 1-[Bis(dimethylamino)
methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexaﬂuorophosphate
(HATU) (20.0mg, 52.6μmol) were dissolved in THF (5mL), and DIEA
(9.1μL, 52.6μmol) was added to the solution. It was stirred for 5min
followed by the addition of ﬂuorescein amine (54.8mg, 157.8μmol) in
THF (2mL). The reaction mixture was stirred for 16 h at room temperature,
and then it was evaporated in vacuo; the crude product was puriﬁed by
column chromatography (CHCl3–MeOH–AcOH 90:9:1) to give 37.0mg
(55%) of pure 6 as an orange solid. Rf 0.41 (CHCl3–MeOH–AcOH 90:9:1); k′
= 8.53 (tR = 12.4min; Vydac 214TP5410 C4 column (100 × 4.6mm, 5 μm),
gradient elution with 1.8%/min ACN (0.08% (v/v) TFA) in H2O (0.1%(v/v)
TFA) starting from 50% ACN, ﬂow rate: 1mL/min, λ = 216 nm); 1H NMR
(500MHz, (CD3)2SO) δ 10.30 (s, 1H), 10.21 (brs, 2H), 8.43 (s, 1H), 8.32 (d,
1H, J= 5.7 Hz), 7.89 (t, 1H, J= 5.4 Hz), 7.79 (s, 1H), 7.74 (d, 1H, J= 8.3 Hz),
7.15 (d, 1H, J= 8.3 Hz), 6.97 (s, 2H), 6.90 (s, 2H), 6.87 (dd, 2H, J= 8.6, 2.6 Hz),
6.73 (dd, 2H, J= 8.6, 1.6 Hz), 5.31 (d, 1H, J= 3.2 Hz), 5.09 (q, 1H, J= 5.8 Hz),
4.47 (t, 2H, J= 5.1 Hz), 4.42 (m, 1H), 3.92 (m, 2H), 3.77 (t, 2H, J= 5.1 Hz),
3.45 (brs, 10H), 3.38 (q, 2H, J= 5.7 Hz), 3.12 (m, 1H), 3.05 (dd, 1H, J= 14.9,
7.1 Hz), 2.71 (m, 2H), 2.43 (t, 2H, J= 6.7 Hz), 2.34 (t, 2H, J= 6.7 Hz), 2.22 (d,
2H, J = 7.6 Hz), 1.92 (m, 1H), 1.85 (m, 1H), 1.76 (m, 3H), [1.60–0.92
(m, 21H): 1.48 (2H), 1.52 (1H), 1.47 (1H), 1.44 (2H), 1.39 (1H), 1.28
(3H), 1.17 (1H), 1.13 (1H), 1.11 (4H), 1.02 (1H), 1.00 (1H), 0.97 (1H),
0.96 (1H), 0.91 (1H)], 0.95 (s, 3H), 0.87 (d, 3H, J = 6.4 Hz), 0.84 (d, 3H,
J = 2.0 Hz), 0.81 (d, 3H, J = 2.0 Hz), 0.65 (s, 3H, 18-H); 13C NMR
(125 MHz, (CD3)2SO) δ 171.5, 171.2, 171.0, 170.6, 169.3, 168.5, 159.2,
152.7, 146.5, 142.8, 142.1, 139.2, 134.1, 129.6, 125.9, 125.5, 125.3,
123.1, 121.9, 116.9, 114.0, 109.1, 101.3, 83.8, 72.8, 69.8, 69.7 (2C),
69.6, 69.3, 69.2, 56.1, 55.9, 55.4, 49.5, 49.4, 42.1, 39.1, 39.0, 38.8,
37.7, 36.6, 36.1, 35.7, 35.0, 34.9, 34.5, 31.8, 31.1, 29.7, 29.2, 27.9,
27.7, 27.4, 27.2, 23.9, 23.3, 22.6, 22.4, 20.9, 19.0, 18.6, 11.7; MS(MALDI)
calcd for C71H89N7O15 1279.64, found 1280.56 [M + H]
+.
Cholesterol anchor 7
The maleimide derivative 5 (25mg, 26.3 μmol), N-hydroxybenzotriazole
(HOBt) (3.6mg, 26.3 μmol) and N,N’-diisopropylcarbodiimide (DIC) (4 μL,
26.3 μmol) were dissolved in DMF (2mL). Then, N-aminopiperidine
(3.1 μL, 29 μmol) was added, and the solution was stirred for 16 h at roomCopyright © 2015 JohnJ. Label Compd. Radiopharm 2015, 58 7–13temperature. It was evaporated in vacuo, and the crude product was
puriﬁed by HPLC on a Discovery Bio Wide Pore C5 column to give
16mg (59%) of pure 7 as a white solid. Rf 0.45 (CHCl3–MeOH–TEA
90:9.9:0.1); k′ = 4.31 (tR = 6.9min; Vydac 214TP5410 C4 column
(100 × 4.6mm, 5 μm), gradient elution with 1.5%/min ACN (0.08% (v/v)
TFA) in H2O (0.1%(v/v) TFA) starting from 60% ACN, ﬂow rate:
1mL/min, λ = 216 nm); 1H NMR (500MHz, CDCl3) δ 7.63 (s, 1H), 7.08 (s,
1H), 6.68 (s, 2H), 6.60 (s, 1H), 6.48 (s, 1H), 5.34 (d, 1H, J = 3.7 Hz), 4.87
(brs, 1H), 4.55 (m, 2H), 4.46 (s, 1H), 3.83 (s, 4H), 3.61 (brs, 10H), 3.42 (q,
2H, J = 4.6 Hz), 3.20 (m, 2H), 2.73 (m, 4H), 2.62 (t, 2H, J = 6.7 Hz), 2.58 (t,
2H, J = 6.7 Hz), 2.47 (t, 2H, J = 7.6 Hz), 2.29 (d, 2H), 1.99 (m, 1H), 1.96 (m,
1H), 1.83 (m, 3H), 1.71 (m, 4H), [1.58–1.01 (m, 20H): 1.55 (3H), 1.50 (1H),
1.47 (2H), 1.43 (m, 3H), 1.32 (1H), 1.30 (2H), 1.23 (1H), 1.14 (1H), 1.11
(4H), 1.09 (1H), 1.05 (1H)], 1.00 (s, 3H), [0.96–0.83 (m, 3H): 0.96 (1H), 0.92
(1H), 0.90 (1H)], 0.88 (d, 3H, J = 6.4 Hz), [0.86 (d, 3H, J = 1.8 Hz), 0.84 (d,
3H, J = 1.8 Hz)], 0.66 (s, 3H); 13C NMR (125MHz, CDCl3) δ 172.7, 172.2,
170.7, 169.9, 156.8 142.7, 139.8, 134.3, 124.3, 122.8, 74.5, 70.6, 70.5, 70.3,
70.0, 69.9, 69.4, 63.4, 56.8, 56.3, 53.6, 50.5, 50.1, 42.4, 39.8, 39.6, 39.4,
38.2, 37.1, 36.7, 36.3, 35.9, 34.6, 34.3, 32.0 (2C), 31.0, 30.0, 28.4, 28.14,
28.12, 27.9, 27.2, 24.4, 24.0, 23.5, 23.0, 22.7, 21.2, 19.4, 18.8, 12.0; MS
(MALDI) calcd for C56H88N8O10 1032.66, found 1033.58 [M + H]
+.
[3H]cholesterol anchor 8
The maleimide derivative 5 (1 mg, 1 μmol) was dissolved in DMF (300 μL)
containing HOBt (0.13mg, 1 μmol), DIC (0.14 μL, 1 μmol) and DIEA
(0.09 μL, 0.5 μmol). Then, [3H]N-aminopiperidine (100MBq) dissolved in
24 μL of DMF was added, and the solution was stirred for 16 h at room
temperature. It was evaporated in vacuo; the crude product was
dissolved in HFIP, and it was puriﬁed by HPLC on a Vydac 214TP5410
column to give 17.4MBq of pure 8. k′ = 4.31 (tR = 6.9min; Vydac
214TP5410 C4 column (100 × 4.6mm, 5 μm), gradient elution with
1.5%/min ACN (0.08% (v/v) TFA) in H2O (0.1%(v/v) TFA) starting from
60% ACN, ﬂow rate: 1 mL/min, λ = 216 nm), s.a. 1.37 TBq/mmol.
Cell culture
SH-SY5Y (ATCC: CRL-2266) human neuroblastoma cells were used to test
the membrane association potency of 6 and 8. Cells were cultured in
DMEM (Sigma Ltd., St. Louis, MO, USA) medium containing 10% FCS,
L-glutamine (2mM), gentamycin (160 μg/mL), 1mM pyruvate and non-
essential amino acids (Sigma Ltd., St. Louis, MO, USA). The cell culture
was maintained at 37 °C in a humidiﬁed atmosphere with 5% CO2.
Live cell imaging with confocal laser scanning microscopy
Twenty thousand cells per well were plated on an 8-well Lab-Tek II
Chambered cover glass. After 48 h incubation at 37 °C, cells were treated
with 1 μM of 6 dissolved in serum-free medium containing 10 μM β-
cyclodextrin for 30min. Cells treated with serum-free medium for
30min were used as a negative control. After treatment and incubation,
cells were washed with serum-free medium, and the nuclei of the cells
were stained for 5min with DRAQ5. Sequential excitation was applied
for ﬂuorescein and DRAQ5. Fluorescein was excited with an Ar ion laser
(488 nm), and emitted photons were collected through a BA 505–525 nm
ﬁlter; DRAQ5 was excited with a He–Ne laser at 633 nm, and emitted
photons were collected through a BA 660 nm ﬁlter.
Membrane incorporation of [3H]cholesterol anchor 8
106 cells per well were plated on a 24-well plate, and after 12 h
incubation at 37 °C, cells were treated with 1–100 nM of 2 or 8 dissolved
in serum-free medium containing 10 μM β-cyclodextrin for 10 and 30min.
Then, cells were washed with serum-free medium and trypsinized. The
resulting cell suspensions were ﬁltered on a GF/B ﬁlter (Whatman) using a
24-well cell harvester (Brandel) and washedwith phosphate-buffered saline
(PBS) pH7.4. Filter discs containing the cells were immersed into Ultima
Gold XR scintillation cocktail, and they were counted in glass vials with awww.jlcr.orgWiley & Sons, Ltd.
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10Packard Tri-Carb 2100 TR LSA. Cells treated with serum-free medium for
30 min were used for background counting.
Results and discussion
Our earlier studies revealed that a maleimide functionalized
ﬂuorescent cholesterol derivative is capable of anchoring
proteins to the plasma membrane of live cells.18 The headgroup
of the anchor molecule contains a diethylene glycol residue,
which increases the polarity of the molecule and exposes the
attached protein towards the extracellular space. When applied
in a form of β-cyclodextrin inclusion complex, the headgroup
ﬂuorescence of the cholesterol anchor can be used for the
unambiguous visualization of the attached protein after cell
membrane delivery. In order to determine the membrane
concentration of the cholesterol anchor, a tritium labelled
analogue (8) was designed. By using this compound, the
quantitation of the membrane incorporated protein anchor can
be achieved by measuring the radioactivity of cell membrane
preparations or intact cells. For this purpose, a deﬁned position
of the radioactive label is crucial. Although [1,2-3H]cholesterol
complexed with β-cyclodextrin was reported to use for the fast
enrichment of cell membranes with labelled cholesterol,21 and
it was also used in studying the cyclodextrin-mediated
cholesterol transfer between different lipid layers22; cholesterol
labelling is not appropriate for our purposes. The headgroup of
the cholesterol anchor can be enzymatically removed via the
hydrolysis of the cholesteryl ester, and as a result the labelled
cholesterol, moiety remains in the cell membrane and the
unlabelled headgroup is released to the cell culture medium. In
this case, the membrane radioactivity is not affected by the
presence or lack of the headgroup, and the process cannot beScheme 1. Preparation of the ﬂuorescein and tritium labelled cholesterol anchors:
30 min; (c) 2 eq DIEA, MeOH, RT, 3 h; (d) HATU, DIEA, THF, RT, 16 h; (e) HOBt, DIC, DM
www.jlcr.org Copyright © 2015 Johdetected, resulting in overestimation of the amount of the
membrane-associated cholesterol anchor. In contrast, if the
tritium label is incorporated into the headgroup of the anchor
molecule, enzymatic removal of the headgroup will result in
decreasing radioactivity of the cell membrane preparation and
also emerging the labelled headgroup in the cell culture medium.
In order to introduce the radioactive label into the cholesterol
anchor headgroup, a convergent synthetic strategy was applied.
The tritium label was incorporated into a small molecule that was
coupled to an anchor fragment bearing both the cholesterol
residue and the bulk of the headgroup. The advantage of this
approach is that tritium incorporation either into the cholesterol
moiety or into other parts of the headgroup is excluded. The
cholesterol amphiphile 4 is an appropriate intermediate, because
primary amine and carboxylic acid functions in the headgroup
are available for the introduction of a radiolabelled or a
ﬂuorescent tag, and a protein conjugation function as well. It
was prepared from Nα-tBoc-protected propargylglycine and
cholesteryl 1-azido-13-oxo-3,6,9-trioxa-12-azahexadecan-16-oate
via a dipolar cycloaddition in the presence of CuSO4 and sodium
ascorbate (Scheme 1). The Nα-tBoc-protecting group was
removed by TFA in DCM, and the amine 4 was liberated in situ
with DIEA during the next step. Then, 4 was used for the
preparation of two constitutionally related tritium or ﬂuorescein
labelled anchors. First, the thiol reactive maleimide group was
coupled to the amine 4, because this way, the co-existence of a
Michael acceptor and a primary amine in an intermediate
compound is excluded that otherwise could lead to self-addition
under the basic conditions of the introduction of the labelling
tag. It was found that the amino function of 4 reacts faster with
an N-hydroxysuccinimide ester than with a maleimide, and
accordingly, the N-acylation of 4 with 3-maleimidopropionic acid(a) NaAsc, CuSO4.5H2O, DMF–CH2Cl2–H2O (1:4:4), RT, 8 h; (b) TFA–CH2Cl2 (1:1), RT,
F, RT, 16 h.
n Wiley & Sons, Ltd. J. Label Compd. Radiopharm 2015, 58 7–13
B. Schäfer et al.N-hydroxysuccinimide ester in DMF resulted in 5. This maleimide
serves as a possible protein conjugation function in biological
applications. In order to avoid the addition of nucleophiles to
the maleimide of 5, an aniline and an alkyl-hydrazine—both are
less basic than primary amines—were used to introduce the
ﬂuorescein and the tritium label, respectively. In a preliminary
study, it turned out that the aniline moiety of 5-aminoﬂuorescein
did not react with the Michael acceptor of N-(2-maleimidoethyl)-
2-aminopent-4-ynamide under the coupling condition applied
for the preparation of 6. Then, the ﬂuorescent anchor 6 was
obtained by coupling of the carboxyl group of 5 with 5-
aminoﬂuorescein in the presence of the coupling agent HATU.
The NMR structure investigation revealed that 5-
aminoﬂuorescein was conjugated to the carboxylic function of 5.
Based on earlier observations on isotopomer radioligands,21–23
the tritium label was introduced via an aliphatic compound
instead of aniline to increase the radiolytic stability of the
labelled anchor molecule. N-Aminopiperidine was chosen for
that purpose, because it is less basic than cyclohexylamine,24,25
and after N-acylation, it results in stable hydrazides. Coupling
of tritium labelled N-aminopiperidine to the carboxylic acid
function of 5 results in an anchor molecule possessing a
headgroup homologous to that of 6, and this way, theScheme 2. Preparation of [
3
H]N-aminopiperidine: (a) Pd/C (10% Pd),
2
H2 (1) or
3
H2
(2), EtOAc, RT, 3 h; (b) KNO2, 1 M HCl, 0 °C, 2 h; (c) LiAlH4, THF, Ar atm, 60 °C, 3.5 h.
Figure 1. ESI mass spectrum of [
2
H]piperidine and the abundance of the
isotopologues;
a
measured intensity,
b
relative intensity corrected with the natural
abundance of
2
H,
13
C.
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11nonspeciﬁc tritium incorporation into the cholesterol moiety or
into the headgroup is not feasible. Before preparing the tritium
labelled anchor by N-acylation of [3H]N-aminopiperidine with 5,
the unlabelled isotopologue 7 was prepared in order to optimize
the reaction conditions and carry out NMR measurements. For
the preparation of the tritium labelled N-aminopiperidine,
4-bromopiperidine was considered as a precursor in a deuterium
labelling experiment (Scheme 2). The 4-bromopiperidine base
was liberated from the hydrobromide salt, and it was reduced
with deuterium gas in the presence of Pd/C (10% Pd) catalyst.
The resulting [2H]piperidine hydrochloride was analysed by
TLC and ESI-MS. The separation of 4-bromopiperidine and
piperidine was achieved on silica gel 60 F254 glass plates in
n-BuOH–AcOH–H2O 2:1:1, as their Rf values were found to be
0.48 and 0.38, respectively. The TLC analysis of the crude [2H]
piperidine hydrochloride revealed that the conversion of
4-bromopiperidine was complete. Furthermore, the deuterium
incorporation level was estimated by an ESI-MS analysis. It
was found that 0.9 deuterium atoms/piperidine molecules were
incorporated on average, but isotopologous species containing
two or three deuterium atoms were also identiﬁed (Figure 1).
These results suggested that this precursor is satisfactory for
achieving an approximate molar activity of 1 TBq/mmol. In
the next step, [3H]N-amino-piperidine was prepared from
4-bromopiperidine (Scheme 2). Reduction of the brominated
piperidine with tritium gas in the presence of Pd/C (10% Pd)
catalyst resulted in tritium labelled piperidine that was
nitrosated. The resulting [3H]N-nitrosopiperidine was then
reduced with LiAlH4, and [
3H]N-aminopiperidine was isolated
as a hydrochloride salt. The carboxylic acid 5 was activated
with HOBt in the presence of DIC, and the resulting active ester
was used in situ for the N-acylation of [3H]N-aminopiperidine to
give the tritium labelled anchor 8. HPLC analysis revealed that
a signiﬁcant amount of tritium labelled N-aminopiperidine
was coupled to 5 (Figure 2). The puriﬁcation of the crude
cholesterol derivative was achieved by RP-HPLC, resulting in
17.4MBq of pure 8 with an isolated radiochemical yield of
17%. The sterical hindrance of the carboxylic acid function of
5 and the more diluted reaction mixture as compared with that
of 6 and 7 resulted in the low yield of 8. Quantitative analysis
of the concentration and radioactivity of the labelled anchor 8
was performed by RP-HPLC via UV and radioactivity detection
using a calibration curve made by 7. The speciﬁc activity of
the tritiated cholesterol anchor 8was found to be 1.37 TBq/mmol
that is higher than the theoretical value. Beyond tritium
substitution of Br in 4-bromopiperidine, catalytic 1H/3H exchange
reactions also took place presumably at positions 2 and 6 of the
piperidine ring. When 2–3 h of reaction time is applied for
catalytic dehalotritiation, the catalytic exchange becomes
signiﬁcant and increases the speciﬁc activity.23 The ESI-MS
analysis of the deuterium labelled piperidine also indicated
catalytic exchange reactions. It is important to note that the
convergent synthetic strategy ensures that all the tritium atoms
are localized in the piperidine ring of the headgroup, because
after the tritium gas reduction of 4-bromopiperidine, further
transformations do not affect the tritium distribution.
The control compound 6, a ﬂuorescent GPI anchor mimetic,
was used to assess the membrane association property of the
designed [3H]anchor. The solubility of 6 was investigated in an
aqueous medium before the imaging application. It was found
that the amphiphile 6 partially dissolved in a serum-free medium
as micellar associates and the remaining portion formedwww.jlcr.orgWiley & Sons, Ltd.
Figure 2. Radio-HPLC chromatogram of (a) the crude and (b) the puriﬁed tritium labelled cholesterol anchor 8. [
3
H]N-aminopiperidine was eluted without retention, and
8 was eluted at tR = 6.90 min.
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12precipitates. The resulting heterogeneous mixture was
incubated with 10 eq β-cyclodextrin that forms water-soluble
inclusion complexes with cholesterol and 3β-hydroxyl-modiﬁed
cholesterol derivatives.26 This way, 0.5mM aqueous solution of
the cholesterol amphiphile was prepared. Then, SH-SY5Y cells
were treated with 1μM of the inclusion complex of 6 for
30min. After delivering to live SH-SY5Y cells, an intensive
membrane staining was observed, that is, 6 incorporated into
the cell membrane similarly to our original anchor18 (Figure 3).
It indicates that a slight modiﬁcation in the α-amino acid
function of the headgroup is tolerated with the retention of
the membrane association properties. The tritium labelled
anchor 8 could also be solubilized in cell culture medium withFigure 3. Confocal laser scanning (left) and differential interference contrast (right) m
followed by a treatment with the nuclear dye DRAQ5 for 5 min at 37 °C. On the image
wileyonlinelibrary.com/journal/jlcr.
www.jlcr.org Copyright © 2015 Johthis method, and it was applied for studying the cell membrane
incorporation of 8. SH-SY5Y cells were incubated with 1–100 nM
of 8 or 2 at 37 °C for 10 and 30min, and then cells were washed
and trypsinized. The membrane incorporated radioactivity was
determined by liquid scintillation counting of the ﬁltered cells.
It was found that 2 was not incorporated into the cell
membranes, as the radioactivity of these cell population was
slightly above the background (Figure 4). However, when cells
were treated with 8, concentration- and time-dependent
incorporation of the radioactive cholesterol anchor was
observed. The radioactivity of the cell cultures was ca. 20%
higher after 30min incubation than after 10min incubation,
indicating fast plasma membrane incorporation of 8.icroscopy of SH-SY5Y cells after 30 min incubation with 1 μM cholesterol anchor 6
, ﬂuorescein is green and nuclei are blue. This ﬁgure is available in colour online at
n Wiley & Sons, Ltd. J. Label Compd. Radiopharm 2015, 58 7–13
Figure 4. Incorporation of the [
3
H]cholesterol anchor 8 to the membrane of SH-
SY5Y cells. Cells were incubated with different concentrations of 2 (grey bars) or
8 (black bars) in the presence of 10 μM β-cyclodextrin followed by liquid
scintillation counting of the washed and trypsinized cells. The error bars represent
SEM values of three parallel measurements.
B. Schäfer et al.Conclusions
Semisynthetic lipoproteins prepared from recombinant proteins
and designed lipid derivatives are valuable probes of the
membrane-associated lipoproteins. In this article, we reported
the synthesis of a novel tritium labelled cholesterol anchor that
contains the radioactive label in the headgroup. It was achieved
in a convergent synthetic approach by the acylation of [3H]N-
aminopiperidine with the 1-hydroxybenzotriazole ester of the
carboxylic acid derivative 5. This structure of the headgroup
features the introduction of the tritium label into the same
position where a ﬂuorophore was introduced in 6. Thus, the
ﬂuorescein and tritium labelled anchors are constitutionally
related, and the ﬂuorescence microscopic images are relevant
to the [3H]cholesterol incorporation data. Each synthetic step
was optimized by using unlabelled standard compounds and
by tracer experiments, and ﬁnally, the target cholesterol
amphiphile 8 was obtained with a radiochemical purity of 98%
and with a chemical purity of 99%. It was demonstrated that
the membrane incorporation of the resulting headgroup labelled
[3H]cholesterol anchor is concentration and time dependent, and
that it can be investigated at low concentrations, below the
working concentration of ﬂuorescent analogues. It is advantageous
because under these conditions, the exogenous introduction of
cholesterol derivative 8 results in low membrane concentration
and thus low level of membrane perturbation, cellular stress.
Acknowledgements
Financial support from the Hungarian Scientiﬁc Research Fund
(K77783), the Hungarian National Development Agency (TÁMOPCopyright © 2015 JohnJ. Label Compd. Radiopharm 2015, 58 7–134.2.2.A-11/1/KONV-2012-0052) and the János Bolyai Research
Scholarship of the Hungarian Academy of Sciences (Cs.T.), and
technical help of Balázs Csibrány in cell culturing are
acknowledged.
Conﬂict of Interest
The authors did not report any conﬂict of interest.
References
[1] T. Kinoshita, M. Fujita, chapter title: Overview of GPI biosynthesis. In
The Enzymes. Volume 26: Glycosylphosphatidylinositol (GPI)
Anchoring of Proteins (Eds.: A. K. Menon, T. Kinoshita, P. Orlean, F.
Tamanoi), Academic Press: New York, 2009, pp. 1–30.
[2] M. E. Medof, T. Kinoshita, V. Nussenzweig, J. Exp. Med. 1984, 160,
1558.
[3] C. W. van den Berg, T. Cinek, M. B. Hallett, V. Horejsi, B. P. Morgan,
J. Cell Biol. 1995, 131, 669.
[4] P. E. Milhiet, M. C. Giocondi, O. Baghdadi, F. Ronzon, B. Roux, C. Le
Grimellec, EMBO Rep. 2002, 3, 485.
[5] C. Metzner, M. M. Mostegl, W. H. Gunzburg, B. Salmons, J. A.
Dangerﬁeld, FASEB J. 2008, 22, 2734.
[6] M. E. Medof, S. Nagarajan, M. L. Tykocinski, FASEB J. 1996, 10, 574.
[7] B. Bader, K. Kuhn, D. J. Owen, H. Waldmann, A. Wittinghofer, J.
Kuhlmann, Nature 2000, 403, 223.
[8] D. R. Premkumar, Y. Fukuoka, D. Sevlever, E. Brunschwig, T. L.
Rosenberry, M. L. Tykocinski, M. E. Medof, J. Cell. Biochem. 2001, 82, 234.
[9] F. R. Taylor, D. Wen, E. A. Garber, A. N. Carmillo, D. P. Baker, R. M.
Arduini, K. P. Williams, P. H. Weinreb, P. Rayhorn, X. Hronowski, A.
Whitty, E. S. Day, A. Boriack-Sjodin, R. I. Shapiro, A. Galdes, R. B.
Pepinsky, Biochemistry 2001, 40, 4359.
[10] C. Peters, A. Wolf, M. Wagner, J. Kuhlmann, H. Waldmann, Proc. Natl.
Acad. Sci. U. S. A. 2004, 101, 8531.
[11] M. J. Grogan, Y. Kaizuka, R. M. Conrad, J. T. Groves, C. R. Bertozzi,
J. Am. Chem. Soc. 2005, 127, 14383.
[12] M. G. Paulick, M. B. Forstner, J. T. Groves, C. R. Bertozzi, Proc. Natl.
Acad. Sci. U. S. A. 2007, 104, 20332.
[13] K. Teruya, K. Nishizawa, K. Doh-ura, Protein J. 2010, 29, 493.
[14] K. Simons, M. J. Gerl, Nat. Rev. Mol. Cell Biol. 2010, 11, 688.
[15] D. Lingwood, K. Simons, Science 2010, 327, 46.
[16] S. Agarwal, C. Schroeder, G. Schlechtingen, T. Braxmeier, G. Jennings,
H. J. Knolker, Bioorg. Med. Chem. Lett. 2013, 23, 5165.
[17] S. B. Sato, K. Ishii, A. Makino, K. Iwabuchi, A. Yamaji-Hasegawa, Y.
Senoh, I. Nagaoka, H. Sakuraba, T. Kobayashi, J. Biol. Chem. 2004,
279, 23790.
[18] B. Schäfer, E. Orbán, A. Borics, K. Huszár, A. Nyeste, E. Welker, Cs.
Tömböly, Bioconj. Chem. 2013, 24, 1684.
[19] G. Tóth, S. Lovas, F. Ötvös, In Methods in Molecular Biology:
Neuropeptide Protocols (Eds.: G. B. Irvine, C. H. Williams), Humana
Press: Totowa, NJ, 1997, pp. 219–230.
[20] Cs. Tömböly, A. Péter, G. Tóth, Peptides 2002, 23, 1573.
[21] A. E. Christian, M. P. Haynes, M. C. Phillips, G. H. Rothblat, J. Lipid Res.
1997, 38, 2264.
[22] R. Leventis, J. R. Silvius, Biophys. J. 2001, 81, 2257.
[23] Cs. Tömböly, R. Dixit, I. Lengyel, A. Borsodi, G. Tóth, J. Label. Compd.
Radiopharm. 2001, 44, 355.
[24] R. Hinman, J. Org. Chem. 1958, 23, 1587–1588.
[25] H. K. Hall Jr., J. Am. Chem. Soc. 1957, 79, 5441.
[26] R. Ravichandran, S. Divakar, J. Incl. Phenom. Mol. Recognit. Chem.
1998, 30, 253.www.jlcr.orgWiley & Sons, Ltd.
13
